-$0.16 EPS Expected for CymaBay Therapeutics Inc (NASDAQ:CBAY) This Quarter

Brokerages expect CymaBay Therapeutics Inc (NASDAQ:CBAY) to announce earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for CymaBay Therapeutics’ earnings. The highest EPS estimate is ($0.11) and the lowest is ($0.19). CymaBay Therapeutics reported earnings of ($0.38) per share in the same quarter last year, which would suggest a positive year over year growth rate of 57.9%. The firm is expected to announce its next quarterly earnings report on Tuesday, November 3rd.

According to Zacks, analysts expect that CymaBay Therapeutics will report full-year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.79) to ($0.58). For the next fiscal year, analysts forecast that the company will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.34) to ($0.75). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow CymaBay Therapeutics.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.07.

CBAY has been the subject of a number of research reports. B. Riley upped their price objective on CymaBay Therapeutics from $9.00 to $13.00 in a research report on Wednesday, September 9th. Stifel Nicolaus increased their price objective on shares of CymaBay Therapeutics from $8.00 to $13.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Zacks Investment Research lowered shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 6th. Piper Sandler began coverage on shares of CymaBay Therapeutics in a report on Thursday, July 30th. They set an “overweight” rating and a $12.00 target price for the company. Finally, Citigroup lifted their price target on shares of CymaBay Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Tuesday, August 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. CymaBay Therapeutics currently has an average rating of “Buy” and a consensus target price of $12.13.

Several large investors have recently added to or reduced their stakes in CBAY. UBS Group AG lifted its holdings in CymaBay Therapeutics by 340.1% in the 1st quarter. UBS Group AG now owns 371,902 shares of the biopharmaceutical company’s stock worth $551,000 after purchasing an additional 287,393 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of CymaBay Therapeutics in the first quarter worth $40,000. State Street Corp boosted its position in shares of CymaBay Therapeutics by 0.8% during the first quarter. State Street Corp now owns 1,421,566 shares of the biopharmaceutical company’s stock worth $2,104,000 after acquiring an additional 11,652 shares during the last quarter. Acadian Asset Management LLC grew its stake in CymaBay Therapeutics by 47.9% during the first quarter. Acadian Asset Management LLC now owns 611,297 shares of the biopharmaceutical company’s stock valued at $906,000 after acquiring an additional 198,002 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in CymaBay Therapeutics by 3,382.3% in the 1st quarter. JPMorgan Chase & Co. now owns 786,408 shares of the biopharmaceutical company’s stock valued at $1,164,000 after acquiring an additional 763,825 shares during the last quarter. Hedge funds and other institutional investors own 85.99% of the company’s stock.

Shares of NASDAQ CBAY traded up $0.15 during midday trading on Wednesday, hitting $6.64. 1,831,434 shares of the stock traded hands, compared to its average volume of 2,903,799. The firm has a market capitalization of $457.41 million, a P/E ratio of -5.77 and a beta of 1.72. CymaBay Therapeutics has a one year low of $1.21 and a one year high of $7.09. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.37 and a current ratio of 18.37. The firm has a 50-day moving average of $5.79 and a two-hundred day moving average of $3.49.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Featured Article: How a Strangle Strategy is different from a Straddle Strategy

Get a free copy of the Zacks research report on CymaBay Therapeutics (CBAY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.